Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Is Quarterly Dosing For Teva's Ajovy Enough To Differentiate It From Other CGRP Inhibitors?

Executive Summary

The US FDA approved Teva's fremanezumab dosed monthly and quarterly versus Amgen's monthly Aimovig, and will launch at the same price. However, it's packaged as a pre-filled syringe instead of an autoinjector, has a higher rate of injection site reactions and it may launch alongside Lilly's Emgality.

Advertisement

Related Content

Teva’s Ajovy Claims 28%-30% New Prescription Share In Competitive CGRP Race
No More Deal? Novartis, Amgen Trade Lawsuits Over Aimovig Agreements
A Trough Year For Teva, With A Turning Point Targeted For 2020
Teva’s Ajovy & Pfizer’s Vizimpro Get EU Thumbs Up From CHMP
Teva Braces For A Bigger Hit As Price Competition Intensifies For Copaxone
Harper, Hooper Exit As Amgen Revenues Rise
ICER Says Amgen/Novartis Migraine Drug Aimovig Is Cost Effective At $5,000 Net Price
Teva Pushes CGRP Timeline Back To End Of 2018
As Amgen Looks To Aimovig's Launch, It May Learn From Repatha's Past
Best-In-Class Or First-In-Class: CGRP Inhibitors Line Up To Win The Migraine Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123857

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel